Business
SPECTRAL TO PRESENT AT RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE ON SEPTEMBER 13
SPECTRAL TO PRESENT AT RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE ON SEPTEMBER 13
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n Sep. 13, 2010 (Canada NewsWire Group) -- \n\nTR.cnwUnderlinedCell TD {\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD {\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD {\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell {\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell {\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell {\n BORDER-BOTTOM: #000000 3px solid\n}\n\nTORONTO, Sept. 13 /CNW/ - Spectral Diagnostics Inc., (TSX: SDI), a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced that Dr. Paul Walker, the Company's President & Chief Executive Officer, will present at the Rodman & Renshaw Annual Investment Conference.\nDr. Walker will discuss Spectral's lead theranostics product that combines the EAA(TM) diagnostic with the Toraymyxin(TM) therapeutic, the initiation of its U.S. Phase III pivotal trial, the world's first theranostics trial in the area of sepsis, and the upcoming milestones for the Company. More than 250,000 patients are diagnosed with severe sepsis and septic shock in the U.S. each year, representing a greater than $1 billion market opportunity for Spectral.\n\nWHEN: Monday September 13, 2010 at 4:55 pm (Eastern Time)\n\nWHERE: The Winslow Salon, The Palace Hotel New York\n\nAn archived version of the power point will be available following the presentation at the Company's web site.\nFor additional information on the conference please visit http://www.rodmanandrenshaw.com/conferences?id=51.\n\nAbout Spectral Diagnostics\n\nSpectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment for severe sepsis and septic shock. Toraymyxin(TM) is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA(TM)), the only FDA cleared diagnostic for the detection of endotoxin, Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.\nToraymyxin(TM) has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively in more than 70,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the ...